Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:6039 |
Name | uveal melanoma |
Definition | A uveal cancer that has_material_basis_in uvea pigment cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer sensory system cancer ocular cancer uveal cancer uveal melanoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600E | YM-254890 | uveal melanoma | no benefit | detail... |
NRAS Q61K | YM-254890 | uveal melanoma | no benefit | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00489944 | Phase II | Cisplatin + Sunitinib + Tamoxifen | Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma | Unknown status | USA | 0 |
NCT01200238 | Phase II | Ganetespib | STA-9090(Ganetespib) in Metastatic Ocular Melanoma | Completed | USA | 0 |
NCT01430416 | Phase I | Sotrastaurin | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | Completed | USA | NLD | GBR | FRA | 0 |
NCT01471054 | Phase II | Dexamethasone intravitreal implant Bevacizumab | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | Terminated | USA | 0 |
NCT01585194 | Phase II | Ipilimumab Nivolumab | Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma | Completed | USA | 0 |
NCT01587352 | Phase II | Vorinostat | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | Active, not recruiting | USA | 0 |
NCT01835145 | Phase II | Dacarbazine Temozolomide Cabozantinib | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye | Completed | USA | CAN | 0 |
NCT01974752 | Phase III | Dacarbazine + Selumetinib | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) | Completed | USA | NLD | ISR | GBR | FRA | FIN | ESP | DEU | CAN | BEL | 1 |
NCT01979523 | Phase II | Trametinib Trametinib + Uprosertib | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | Completed | USA | GBR | FRA | 0 |
NCT02068586 | Phase II | Valproic acid Sunitinib | Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma | Active, not recruiting | USA | 0 |
NCT02223819 | Phase II | Crizotinib | Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy | Completed | USA | 0 |
NCT02273219 | Phase I | Alpelisib + Sotrastaurin | Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | Completed | USA | 0 |
NCT02359851 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | Terminated | USA | 0 |
NCT02363283 | Phase II | Glembatumumab vedotin | Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | Completed | USA | 0 |
NCT02561234 | Phase I | Pegzilarginase | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02570308 | Phase I | Tebentafusp | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | Completed | USA | GBR | ESP | DEU | CAN | 0 |
NCT02601378 | Phase I | IDE196 + Siremadlin IDE196 | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. | Terminated | USA | NOR | NLD | FRA | ESP | AUS | 0 |
NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Recruiting | AUS | 0 |
NCT02768766 | Phase I | Selumetinib | Intermittent Selumetinib for Uveal Melanoma | Completed | USA | 0 |
NCT02913417 | Phase Ib/II | Ipilimumab + Nivolumab + Yttrium-90 microsphere therapy | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | Unknown status | USA | 0 |
NCT03022565 | Phase I | Vorinostat | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | Withdrawn | 0 | |
NCT03052127 | Phase I | AU-011 | Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma | Completed | USA | 0 |
NCT03068624 | Phase I | Aldesleukin + Cyclophosphamide + Ipilimumab | Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
NCT03070392 | Phase II | Dacarbazine Ipilimumab Pembrolizumab Tebentafusp | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 2 |
NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
NCT03408587 | Phase I | Coxsackievirus A21 + Ipilimumab | CAVATAK and Ipilimumab in Uveal Melanoma Metastatic to the LIver (VLA-024 CLEVER) (CLEVER) | Completed | USA | 0 |
NCT03417739 | Phase II | Ulixertinib | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
NCT03635632 | Phase I | C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | Active, not recruiting | USA | 0 |
NCT03712904 | Phase II | Aflibercept | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma | Completed | USA | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03922880 | Phase I | ADI-PEG 20 + Ipilimumab + Nivolumab | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | Completed | USA | 0 |
NCT03947385 | Phase Ib/II | IDE196 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Recruiting | USA | CAN | AUS | 0 |
NCT04109456 | Phase I | BI 853520 + Cobimetinib BI 853520 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | Recruiting | USA | AUS | 0 |
NCT04116320 | Phase I | unspecified PD-1 antibody Imiquimod Imiquimod + unspecified PD-1 antibody | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003) | Active, not recruiting | USA | 0 |
NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Recruiting | USA | 0 |
NCT04283890 | Phase Ib/II | Melphalan Ipilimumab + Melphalan + Nivolumab | PHP and Immunotherapy in Metastasized UM | Recruiting | NLD | 0 |
NCT04328844 | Phase I | IOA-244 | A Study to Assess a PI3Kdelta Inhibitor (IOA-244) in Patients With Metastatic Cancers | Active, not recruiting | ITA | GBR | 0 |
NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | GBR | ESP | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04551352 | Phase I | RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | Completed | USA | ESP | DNK | CAN | BEL | AUS | 0 |
NCT04552223 | Phase II | Nivolumab + Relatlimab | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
NCT04589832 | Phase Ib/II | Entrectinib + PAC-1 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | Terminated | USA | 0 |
NCT04720417 | Phase II | Defactinib + RO5126766 | Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
NCT04879017 | Phase I | FHD-286 | FHD-286 in Subjects With Metastatic Uveal Melanoma | Terminated | USA | NLD | FRA | 0 |
NCT04935229 | Phase I | Ipilimumab + Nivolumab + SD-101 | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
NCT04987996 | Phase II | Pembrolizumab Belapectin + Pembrolizumab | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | Withdrawn | USA | 0 |
NCT04993677 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + SEA-CD40 Pembrolizumab + SEA-CD40 | A Study of SEA-CD40 Given With Other Drugs in Cancers | Active, not recruiting | USA | SWE | FRA | ESP | DEU | CAN | 0 |
NCT05004025 | Phase I | Ipilimumab + Nivolumab | Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | Recruiting | USA | 0 |
NCT05047536 | Phase I | KZR-261 | KZR-261 in Subjects With Advanced Solid Malignancies | Active, not recruiting | USA | 0 |
NCT05077280 | Phase II | Ipilimumab + Nivolumab | A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma | Recruiting | USA | 0 |
NCT05170334 | Phase II | Belinostat + Binimetinib | Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma | Recruiting | USA | 0 |
NCT05187884 | Phase II | IDE196 | Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma (NADOM) | Active, not recruiting | AUS | 0 |
NCT05282901 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) (PLUME) | Recruiting | FRA | 0 |
NCT05308901 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naive Metastatic Uveal Melanoma | Recruiting | USA | 0 |
NCT05315258 | Phase II | Tebentafusp | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) | Recruiting | GBR | 0 |
NCT05323045 | Phase I | BYON3521 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | Active, not recruiting | NLD | ITA | GBR | BEL | 0 |
NCT05415072 | Phase Ib/II | DYP688 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | AUS | 0 |
NCT05482074 | Phase II | Olaparib | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Withdrawn | 0 | |
NCT05524935 | Phase II | Olaparib + Pembrolizumab | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | Recruiting | USA | 0 |
NCT05542342 | Phase II | Sitravatinib + Tislelizumab | Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (SITISVEAL) | Active, not recruiting | ESP | 0 |
NCT05576077 | Phase I | Pembrolizumab + TBio-4101 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) | Recruiting | USA | CAN | 0 |
NCT05607095 | Phase I | Lifileucel | Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma | Recruiting | USA | 0 |
NCT05907954 | Phase II | IDE196 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Recruiting | USA | NLD | ITA | GBR | FRA | DEU | CAN | AUS | 0 |
NCT05987332 | Phase II | Dacarbazine Pembrolizumab Ipilimumab + Nivolumab Crizotinib + IDE196 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Recruiting | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 0 |
NCT06070012 | Phase II | Tebentafusp | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | Not yet recruiting | USA | 0 |
NCT06121180 | Phase II | Aflibercept + Cemiplimab | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | Recruiting | USA | 0 |
NCT06414590 | Phase II | Tebentafusp | Neoadjuvant Tebentafusp for Uveal Melanoma | Not yet recruiting | USA | 0 |
NCT06519266 | Phase III | Ipilimumab + Melphalan + Nivolumab Ipilimumab + Nivolumab | PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases (SCANDIUM-III) | Not yet recruiting | SWE | 0 |
NCT06581406 | Phase II | Nivolumab + RP2 Ipilimumab + Nivolumab | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (RP2-202) | Recruiting | USA | 0 |
NCT06626516 | Phase Ib/II | Tebentafusp Sargramostim + Tebentafusp Carmustine + Tebentafusp | Tebentafusp-tebn With LDT in Metastatic UM | Not yet recruiting | USA | 0 |
NCT06627244 | Phase II | Tebentafusp | Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | Not yet recruiting | USA | 0 |